Table 4.
Multivariate Cox regression models for prediction of thrombotic risk for composite arterial and venous thrombotic outcome among prefibrotic and overt fibrotic myelofibrosis patients.
| Variables | Prefibrotic PMF | Overt Fibrotic Myelofibrosis |
|---|---|---|
| ANC (×109/L) | Cut-off >8.33; p = 0.036 * HR 13.08, 95% CI (1.18–144.94) |
Cut-off >8.8; p = 0.004 * HR 4.49, 95% CI (1.62–12.45) |
| ALC(×109/L) | Cut-off >2.58; p = 0.049 * HR 20.63, 95% CI (1.01–420.74) |
Cut-off ≤1.43; p = 0.003 * HR 4.15, 95% CI (1.65–10.47) |
| Platelet count (×109/L) | Cut-off >752; p = 0.043 * HR 10.5, 95% CI (1.07–103.11) |
Cut-off ≤385; p = 0.004 * HR 4.68, 95% CI (1.61–13.66) |
| Age ≥ 60 years |
p = 0.184 HR 6.94, 95% CI (0.39–121.71) |
p = 0.846 HR 1.11, 95% CI (0.36–3.44) |
| History of thrombosis |
p = 0.431 HR 0.17, 95% CI (0.0–13.41) |
p = 0.231 HR 1.81, 95% CI (0.68–4.80) |
| Male sex |
p = 0.441 HR 3.11, 95% CI (0.17–56.23) |
p = 0.477 HR 0.72, 95% CI (0.29–1.77) |
| JAK2 mutated |
p = 0.735 HR 1.48, 95% CI (0.14–14.75) |
p = 0.919 HR 1.06, 95% CI (0.30–3.68) |
| Classic CV risk factors |
p = 0.491 HR 2.82, 95% CI (0.14–54.62) |
p = 0.747 HR 1.16, 95% CI (0.45–2.96) |
| CKD |
p = 0.569 HR 1.9, 95% CI (0.21–17.41) |
p < 0.001 * HR 9.07, 95% CI (3.26–25.18) |
* statistically significant at level p < 0.05. Abbreviations: PMF—primary myelofibrosis, ANC—absolute neutrophil count, HR—hazard ratio, CI—confidence interval, ALC—absolute lymphocyte count, JAK2—Janus kinase 2, CV—cardiovascular, CKD—chronic kidney disease.